EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Liraglutide in Adults With Obesity: A Multicentre, Single‐Arm, Post‐Marketing Surveillance Study in Taiwan

Shih-Te Tu, Chiao-Fan Chiu iD, Chu-Kuang Chou iD, Hai-Hua Chuang iD, Shu-Wei Hu iD, Wen-Ching Ko, Chun-Ying Lee iD, Wen-Yuan Lin iD, Yen-Jen Sung, Thing-Fong Tzeng, Weu Wang, Hsiang-Fan Wu iD und 4 weitere

Endocrinology, Diabetes & Metabolism · 2026-09 · 9 (5)

DOI: 10.1002/edm2.70333 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 19.09.2026. Verfasst von Shih-Te Tu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan. Hauptthemen laut MEDLINE: Liraglutide, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Pharma Taiwan, Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This prospective study (NCT06283641) was the first real‐world, multicentre, post‐marketing surveillance of GLP‐1 receptor agonist liraglutide as an adjunct for weight management in adults with obesity in Taiwan.

Methods

Data were collected from 14 sites at baseline, week 13 and week 26 (February 2024–January 2025). Safety and effectiveness outcomes, including adverse event (AE) incidence proportions (IPs) and body weight (BW) change, were investigated.

Results

Among 259 adults, 61.0% were female (mean ± SD age 42.6 ± 11.3 years, BW 90.4 ± 17.6 kg, BMI 33.0 ± 4.7 kg/m 2 ). Dyslipidaemia (38.2%), hypertension (26.3%), and diabetes (21.2%) were common. Mean daily and maximum doses were 1.4 ± 0.5 and 1.8 ± 0.7 mg/day, respectively. Overall IP of AEs was 11.2%; 90.9% of events were mild. General/injection‐site and gastrointestinal events were most frequent. Medication cost (49.0%) was the predominant factor for dose non‐escalation. At weeks 13 and 26, mean BW loss was −5.7 ± 3.5 and −8.5 ± 5.7 kg (both p < 0.0001; ≥ 5% BW loss in 58.4% and 76.7%) and mean systolic blood pressure decrease was 9.0 ± 16.7 and 10.4 ± 18.9 mmHg, respectively.

Conclusion

Liraglutide at < 3.0 mg/day was well‐tolerated, with BW reduction observed over 26 weeks in Taiwanese adults. Medication cost is a barrier to long‐term obesity management and a significant consideration for health policies in Taiwan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideObesityHypoglycemic AgentsHumansFemaleProduct Surveillance, PostmarketingTaiwanAdultMiddle AgedMaleProspective StudiesGlucagon-Like Peptide-1 Receptor AgonistsWeight Loss

Stichwörter der Autor:innen

GLP‐1 analogobesityreal‐world evidence

Substanzen

LiraglutideHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
  • Division of Pediatric Endocrinology and Genetics, Department of Pediatrics, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan.
  • Obesity Center, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan.

ORCID-Profile: Chiao-Fan Chiu, Chu-Kuang Chou, Hai-Hua Chuang, Shu-Wei Hu, Chun-Ying Lee, Wen-Yuan Lin, Hsiang-Fan Wu, Chet Joe Sim, Kuo-Chin Huang

Förderung

  • Novo Nordisk Pharma Taiwan, Ltd.

Zitieren

APA

Tu, S. T., Chiu, C. F., Chou, C. K., Chuang, H. H., Hu, S. W., Ko, W. C., Lee, C. Y., Lin, W. Y., Sung, Y. J., Tzeng, T. F., Wang, W., Wu, H. F., Yeung, C. Y., Chen, B., Sim, C. J., & Huang, K. C. (2026). Liraglutide in Adults With Obesity: A Multicentre, Single‐Arm, Post‐Marketing Surveillance Study in Taiwan. Endocrinology, Diabetes & Metabolism, 9(5). https://doi.org/10.1002/edm2.70333

Vancouver

Tu ST, Chiu CF, Chou CK, Chuang HH, Hu SW, Ko WC, et al. Liraglutide in Adults With Obesity: A Multicentre, Single‐Arm, Post‐Marketing Surveillance Study in Taiwan. Endocrinology, Diabetes & Metabolism. 2026;9(5). doi:10.1002/edm2.70333

BibTeX
@article{Tu2026,
  author = {Tu, Shih-Te and Chiu, Chiao-Fan and Chou, Chu-Kuang and Chuang, Hai-Hua and Hu, Shu-Wei and Ko, Wen-Ching and Lee, Chun-Ying and Lin, Wen-Yuan and Sung, Yen-Jen and Tzeng, Thing-Fong and Wang, Weu and Wu, Hsiang-Fan and Yeung, Chun-Yan and Chen, Bill and Sim, Chet Joe and Huang, Kuo-Chin},
  title = {Liraglutide in Adults With Obesity: A Multicentre, Single‐Arm, Post‐Marketing Surveillance Study in Taiwan},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  volume = {9},
  number = {5},
  doi = {10.1002/edm2.70333}
}
Kostenlos starten →